Purpose of the Study

Helios Clinical Research is conducting a clinical research study related to advanced melanoma. The purpose of this study is to compare progression-free survival (PFS) of an investigational drug + pembrolizumab to placebo + pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma. The research team is seeking participants who meet the eligibility criteria, including participants ≥ 12 years of age, to learn whether they may qualify.

Study Requirements

  • Be ≥ 12 years of age on the day of signing of informed consent/assent
  • Have a life expectancy of at least 3 months
  • Have histologically or cytologically confirmed Stage 3 unresectable or Stage 4 metastatic melanoma 

Potential Benefits of Participation

Maginfying

Access to new treatments that are
not yet available to the general public.

Hand Heart

Personalized medical attention from
leading healthcare professionals.

Helios

Compensation provided to qualified participants

Study Locations

These studies are currently enrolling at the following sites:

The Oncology Institute Powered by Helios - Whittier, CA
The Oncology Institute Powered by Helios - Long Beach, CA
The Oncology Institute Powered by Helios - Glendale, CA
The Oncology Institute Powered by Helios - San Gabriel, CA
The Oncology Institute Powered by Helios - Santa Ana, CA
The Oncology Institute Powered by Helios - Fountain Valley, CA

About Helios Clinical

Helios Clinical is dedicated to advancing medical research through innovative clinical trials.
Our mission is to discover new ways to improve patient health and outcomes.
We collaborate with leading healthcare professionals and scientists
to ensure the highest standards of research and care for our participants.